Drug Research
Sanofi to focus its COVID-19 development efforts on the...
Recent positive interim results of Sanofi’s mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company’s platform robust capabilities and strategy in mRNA.
Taking into account...
Drug Research
Syndax and Incyte Announce Global Collaboration to Develop and...
Syndax Pharmaceuticals, Inc. and Incyte announced that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R...
Drug Research
Union therapeutics signs deal with Innovent to develop orismilast...
Union therapeutics has signed a strategic partnership and license agreement with Innovent Biologics to develop and commercialise its therapy, orismilast, in China.
A potent and selective...
Drug Research
InSilicoTrials and Galileo Research announce their partnership
Innovation and cutting-edge technology to reduce Research and Development time and costs: InSilicoTrials, a company with broad expertise in Computational Modeling and Simulation, IT and...
Drug Research
Velocity Clinical Research’s multi-site acquisitions signal new frontier for...
Velocity Clinical Research announces it has acquired two multi-site companies, VitaLink Research and the National Research Institute, for an undisclosed amount. The double acquisition adds...
Drug Research
FDA Approves Samsung Bioepis and Biogens BYOOVIZ, LUCENTIS Biosimilar
Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i , for the treatment...
Drug Research
Biocon Biologics and Serum Institute Life Sciences Announce Strategic...
Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.